Citius Pharmaceuticals Inc expected to post a loss of 58 cents a share - Earnings Preview

Reuters02-10

Citius Pharmaceuticals Inc CTXR.OQ CTXR.O is expected to show a rise in quarterly revenue when it reports results on February 12 (estimated) for the period ending December 31 2024
The Cranford New Jersey-based company is expected to report revenue of $7.061 million, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Citius Pharmaceuticals Inc is for a loss of 58 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had fallen by about 50.0% in the last three months.
Wall Street's median 12-month price target for Citius Pharmaceuticals Inc is $8.50, above its last closing price of $2.67.

Previous quarterly performance (using preferred earnings measure in US dollars).

QUARTER ENDING	STARMINESMARTESTIMATE®	LSEG IBES ESTIMATE	ACTUAL	BEAT, MET, MISSED	SURPRISE %
Sep. 30 2024	-1.73	-1.50	-1.59	Missed	-6.1
Jun. 30 2024	-1.24	-1.25	-1.50	Missed	-20
Mar. 31 2024	-1.50	-1.50	-1.25	Beat	16.7
Dec. 31 2023	3.25	3.25	-1.50	Missed	-146.2
Sep. 30 2023		-0.50	-2.00	Missed	-300
Jun. 30 2023	-1.42	-1.37	-1.50	Missed	-9.1
Mar. 31 2023	-0.86	-0.87	-1.75	Missed	-100

This summary was machine generated February 10 at 11:06 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2510830974?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-02-10 19:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2510830974","market":"us","top_or_hot":-1,"title":"Citius Pharmaceuticals Inc  expected to post a loss of 58 cents a share - Earnings Preview","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Citius Pharmaceuticals Inc <ctxr.oq> expected to post a loss of 58 cents a share - Earnings Preview </ctxr.oq></title></head><body><ul><li><p>Citius Pharmaceuticals Inc <span>CTXR.OQ</span> <span>CTXR.O</span> is expected to show a rise in quarterly revenue when it reports  results on February 12 (estimated) for the period ending December 31 2024</p></li><li><p>The Cranford New Jersey-based  company is expected to report revenue of $7.061 million, according to the mean estimate from 3 analysts, based on LSEG data.</p></li><li><p>LSEG's mean analyst estimate for Citius Pharmaceuticals Inc is for a loss of 58 cents per share. </p></li><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts had fallen by about 50.0% in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Citius Pharmaceuticals Inc is $8.50, above its last closing price of $2.67. </p></li></ul><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><table><tbody><tr><td><p>QUARTER ENDING</p></td><td><p>STARMINESMARTESTIMATE®</p></td><td><p>LSEG IBES ESTIMATE </p></td><td><p>ACTUAL</p></td><td><p>BEAT, MET, MISSED</p></td><td><p>SURPRISE %</p></td></tr><tr><td><p>Sep. 30 2024</p></td><td><p>-1.73</p></td><td><p>-1.50</p></td><td><p>-1.59</p></td><td><p>Missed</p></td><td><p>-6.1</p></td></tr><tr><td><p>Jun. 30 2024</p></td><td><p>-1.24</p></td><td><p>-1.25</p></td><td><p>-1.50</p></td><td><p>Missed</p></td><td><p>-20</p></td></tr><tr><td><p>Mar. 31 2024</p></td><td><p>-1.50</p></td><td><p>-1.50</p></td><td><p>-1.25</p></td><td><p>Beat</p></td><td><p>16.7</p></td></tr><tr><td><p>Dec. 31 2023</p></td><td><p>3.25</p></td><td><p>3.25</p></td><td><p>-1.50</p></td><td><p>Missed</p></td><td><p>-146.2</p></td></tr><tr><td><p>Sep. 30 2023</p></td><td></td><td><p>-0.50</p></td><td><p>-2.00</p></td><td><p>Missed</p></td><td><p>-300</p></td></tr><tr><td><p>Jun. 30 2023</p></td><td><p>-1.42</p></td><td><p>-1.37</p></td><td><p>-1.50</p></td><td><p>Missed</p></td><td><p>-9.1</p></td></tr><tr><td><p>Mar. 31 2023</p></td><td><p>-0.86</p></td><td><p>-0.87</p></td><td><p>-1.75</p></td><td><p>Missed</p></td><td><p>-100</p></td></tr></tbody></table><p>This summary was machine generated February 10 at 11:06 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Citius Pharmaceuticals Inc  expected to post a loss of 58 cents a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCitius Pharmaceuticals Inc  expected to post a loss of 58 cents a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-02-10 19:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Citius Pharmaceuticals Inc <ctxr.oq> expected to post a loss of 58 cents a share - Earnings Preview </ctxr.oq></title></head><body><ul><li><p>Citius Pharmaceuticals Inc <span>CTXR.OQ</span> <span>CTXR.O</span> is expected to show a rise in quarterly revenue when it reports  results on February 12 (estimated) for the period ending December 31 2024</p></li><li><p>The Cranford New Jersey-based  company is expected to report revenue of $7.061 million, according to the mean estimate from 3 analysts, based on LSEG data.</p></li><li><p>LSEG's mean analyst estimate for Citius Pharmaceuticals Inc is for a loss of 58 cents per share. </p></li><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts had fallen by about 50.0% in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Citius Pharmaceuticals Inc is $8.50, above its last closing price of $2.67. </p></li></ul><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><table><tbody><tr><td><p>QUARTER ENDING</p></td><td><p>STARMINESMARTESTIMATE®</p></td><td><p>LSEG IBES ESTIMATE </p></td><td><p>ACTUAL</p></td><td><p>BEAT, MET, MISSED</p></td><td><p>SURPRISE %</p></td></tr><tr><td><p>Sep. 30 2024</p></td><td><p>-1.73</p></td><td><p>-1.50</p></td><td><p>-1.59</p></td><td><p>Missed</p></td><td><p>-6.1</p></td></tr><tr><td><p>Jun. 30 2024</p></td><td><p>-1.24</p></td><td><p>-1.25</p></td><td><p>-1.50</p></td><td><p>Missed</p></td><td><p>-20</p></td></tr><tr><td><p>Mar. 31 2024</p></td><td><p>-1.50</p></td><td><p>-1.50</p></td><td><p>-1.25</p></td><td><p>Beat</p></td><td><p>16.7</p></td></tr><tr><td><p>Dec. 31 2023</p></td><td><p>3.25</p></td><td><p>3.25</p></td><td><p>-1.50</p></td><td><p>Missed</p></td><td><p>-146.2</p></td></tr><tr><td><p>Sep. 30 2023</p></td><td></td><td><p>-0.50</p></td><td><p>-2.00</p></td><td><p>Missed</p></td><td><p>-300</p></td></tr><tr><td><p>Jun. 30 2023</p></td><td><p>-1.42</p></td><td><p>-1.37</p></td><td><p>-1.50</p></td><td><p>Missed</p></td><td><p>-9.1</p></td></tr><tr><td><p>Mar. 31 2023</p></td><td><p>-0.86</p></td><td><p>-0.87</p></td><td><p>-1.75</p></td><td><p>Missed</p></td><td><p>-100</p></td></tr></tbody></table><p>This summary was machine generated February 10 at 11:06 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CTXR","symbol_name":"Citius Pharmaceuticals, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nL8N3P10UF:1","article_id":"2510830974","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2510830974","pubTimestamp":1739185565,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Citius Pharmaceuticals Inc  expected to post a loss of58cents a share - Earnings Preview Citius Pharmaceuticals Inc CTXR.OQ CTXR.O is expected to show a rise in quarterly revenue when it reports  resu","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CTXR":"Citius Pharmaceuticals, Inc."},"translate_title":"Citius Pharmaceuticals Inc预计每股亏损58美分-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTXR":0.9},"content_text":"Citius Pharmaceuticals Inc  expected to post a loss of 58 cents a share - Earnings Preview Citius Pharmaceuticals Inc CTXR.OQ CTXR.O is expected to show a rise in quarterly revenue when it reports  results on February 12 (estimated) for the period ending December 31 2024The Cranford New Jersey-based  company is expected to report revenue of $7.061 million, according to the mean estimate from 3 analysts, based on LSEG data.LSEG's mean analyst estimate for Citius Pharmaceuticals Inc is for a loss of 58 cents per share. The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  The mean earnings estimate of analysts had fallen by about 50.0% in the last three months. Wall Street's median 12-month price target for Citius Pharmaceuticals Inc is $8.50, above its last closing price of $2.67. Previous quarterly performance (using preferred earnings measure in US dollars). QUARTER ENDINGSTARMINESMARTESTIMATE®LSEG IBES ESTIMATE ACTUALBEAT, MET, MISSEDSURPRISE %Sep. 30 2024-1.73-1.50-1.59Missed-6.1Jun. 30 2024-1.24-1.25-1.50Missed-20Mar. 31 2024-1.50-1.50-1.25Beat16.7Dec. 31 20233.253.25-1.50Missed-146.2Sep. 30 2023-0.50-2.00Missed-300Jun. 30 2023-1.42-1.37-1.50Missed-9.1Mar. 31 2023-0.86-0.87-1.75Missed-100This summary was machine generated February 10 at 11:06 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2510830974"}